ORSIRO Sirolimus Eluting Coronary Stent System
Biotronik AG · Decision date Sep 24, 2026
What did the FDA decide?
The FDA recorded a 30-Day Notice decision, OK30, dated 2026-09-24, for the ORSIRO Sirolimus Eluting Coronary Stent System under application P170030/S066, submitted by Biotronik AG. The product is a coronary drug-eluting stent in the cardiovascular specialty, product code NIQ. The supplement type is a 30-Day Notice, and the recorded reason is a process change affecting manufacturer, sterilizer, packager or supplier.
The stated scope is changes to solvent preparation and drug coating application. This entry covers that manufacturing process change within the existing P170030 application; it is not a new approval of the whole stent system, and the source does not describe clinical data, coating specifications or the effect on finished-device performance. The source also does not include the decision documents, so the review basis behind OK30 remains unknown from this record.
FDA approval order statement
changes to solvent preparation and drug coating application
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Cardiovascular
- Decision date
- Sep 24, 2026
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P170030/S066
- Regulatory pathway
- PMA supplement
- Applicant
- Biotronik AG
- Product code
- NIQ
- Decision code
- OK30
- Decision date
- Sep 24, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Coronary drug-eluting stent.
- Applicant
- Biotronik AG
- Product code
- NIQ
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P170030. Subsequent supplements may change the device or its indications.
FDA decision timeline
P170030 · Original PMA
ORSIRO Sirolimus Eluting Coronary Stent System
P170030/S066 received
Application receipt date recorded by FDA.
P170030/S066 · FDA decision
30-Day Notice
Timeline entries are records held by MedtechLedger for P170030. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170030
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biotronik AG | PMA approval | Feb 22, 2019 | FDA |
Explore the linked device profile
Other records with product code NIQ
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Medtronic Vascular | PMA supplement | Oct 16, 2026 | FDA | |
| Abbott Vascular | PMA supplement | Oct 1, 2026 | FDA | |
| Medtronic Vascular | PMA approval | Apr 28, 2017 | FDA | |
| Abbott Vascular | PMA approval | Nov 1, 2011 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Biotronik AG
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Ackerstrasse 6, Bülach, 8180
Sources and methodology
- Original FDA record: P170030/S066
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



